Synaptic Biomarkers in CSF Aid in Diagnosis, Correlate with Cognition and Predict Progression in MCI and Alzheimer's Disease

Overview

Journal Alzheimers Dement (N Y)

Date 2019 Dec 20

PMID 31853477

Citations 59

Authors

Douglas Galasko

Meifang Xiao

Desheng Xu

Denis Smirnov

David P Salmon

Nele Dewit

Jeroen Vanbrabant

Dirk Jacobs

Hugo Vanderstichele

Eugeen Vanmechelen

Paul Worley

Affiliations

Soon will be listed here.

Abstract

Introduction: Amyloid, Tau, and neurodegeneration biomarkers can stage Alzheimer's Disease (AD). Synaptic biomarkers may help track cognition.

Methods: In cognitively normal controls, Mild Cognitive Impairment (MCI) and AD, we investigated CSF biomarkers in relation to cognitive measures and as predictors of cognitive and global decline.

Results: There were 90 normal controls (mean age 73.0, 58% women), 57 MCI (mean age 74.3, 35% women), and 46 AD (mean age 70.7, 41% women). CSF Aβ1-42 and Neuronal Pentraxin 2 (NPTX2) were decreased, and CSF Tau, neurogranin, and SNAP25 increased in AD versus controls. Aβ1-42/Tau or NPTX2/Tau discriminated AD and controls best. NPTX2/Tau correlated strongly with cognition in AD and MCI and predicted a 2-3-year decline. We replicated findings in the ADNI cohort.

Discussion: CSF synaptic biomarkers, particularly NPTX2, which regulates synaptic homeostasis, relate to cognition and predict progression in AD beyond Aβ1-42 and Tau. This is relevant for prognosis and clinical trials.

Citing Articles

Evaluation of cerebrospinal fluid levels of VAMP-2 and SNAP-25 in a dementia with Lewy bodies clinical cohort stratified by Alzheimer's pathophysiological biomarkers.

Gonzalez A, Goossens J, Campuzano E, Sala I, Sanchez-Saudinos M, Rodriguez-Baz I Alzheimers Res Ther. 2025; 17(1):51.

PMID: 39994784 PMC: 11849174. DOI: 10.1186/s13195-025-01685-y.

Novel plasma biomarkers of amyloid plaque pathology and cortical thickness: Evaluation of the NULISA targeted proteomic platform in an ethnically diverse cohort.

Zeng X, Sehrawat A, Lafferty T, Chen Y, Rawat M, Kamboh M Alzheimers Dement. 2025; 21(2):e14535.

PMID: 39989429 PMC: 11848535. DOI: 10.1002/alz.14535.

Phospho-tau serine-262 and serine-356 as biomarkers of pre-tangle soluble tau assemblies in Alzheimer's disease.

Islam T, Hill E, Abrahamson E, Servaes S, Smirnov D, Zeng X Nat Med. 2025; 31(2):574-588.

PMID: 39930142 PMC: 11835754. DOI: 10.1038/s41591-024-03400-0.

Exploring the Relationship Between Serum Neuronal Pentraxin 2 and Poststroke Cognitive Impairment in Patients With First-Episode Acute Ischemic Stroke.

Li J, Ma W, Gu S Brain Behav. 2025; 15(2):e70305.

PMID: 39924979 PMC: 11808180. DOI: 10.1002/brb3.70305.

Skull bone marrow and skull meninges channels: redefining the landscape of central nervous system immune surveillance.

Liu L, Zhang X, Chai Y, Zhang J, Deng Q, Chen X Cell Death Dis. 2025; 16(1):53.

PMID: 39875352 PMC: 11775313. DOI: 10.1038/s41419-025-07336-2.

References

Suarez-Calvet M, Morenas-Rodriguez E, Kleinberger G, Schlepckow K, Caballero M, Franzmeier N . Early increase of CSF sTREM2 in Alzheimer's disease is associated with tau related-neurodegeneration but not with amyloid-β pathology. Mol Neurodegener. 2019; 14(1):1. PMC: 6327425. DOI: 10.1186/s13024-018-0301-5. View

Pelkey K, Barksdale E, Craig M, Yuan X, Sukumaran M, Vargish G . Pentraxins coordinate excitatory synapse maturation and circuit integration of parvalbumin interneurons. Neuron. 2015; 85(6):1257-72. PMC: 4368480. DOI: 10.1016/j.neuron.2015.02.020. View

Zhang H, Therriault J, Kang M, Ng K, Pascoal T, Rosa-Neto P . Cerebrospinal fluid synaptosomal-associated protein 25 is a key player in synaptic degeneration in mild cognitive impairment and Alzheimer's disease. Alzheimers Res Ther. 2018; 10(1):80. PMC: 6097333. DOI: 10.1186/s13195-018-0407-6. View

Olsson B, Portelius E, Cullen N, Sandelius A, Zetterberg H, Andreasson U . Association of Cerebrospinal Fluid Neurofilament Light Protein Levels With Cognition in Patients With Dementia, Motor Neuron Disease, and Movement Disorders. JAMA Neurol. 2018; 76(3):318-325. PMC: 6440232. DOI: 10.1001/jamaneurol.2018.3746. View

Mattsson N, Insel P, Palmqvist S, Portelius E, Zetterberg H, Weiner M . Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease. EMBO Mol Med. 2016; 8(10):1184-1196. PMC: 5048367. DOI: 10.15252/emmm.201606540. View

Tarawneh R, DAngelo G, Crimmins D, Herries E, Griest T, Fagan A . Diagnostic and Prognostic Utility of the Synaptic Marker Neurogranin in Alzheimer Disease. JAMA Neurol. 2016; 73(5):561-71. PMC: 4861689. DOI: 10.1001/jamaneurol.2016.0086. View

Verret L, Mann E, Hang G, Barth A, Cobos I, Ho K . Inhibitory interneuron deficit links altered network activity and cognitive dysfunction in Alzheimer model. Cell. 2012; 149(3):708-21. PMC: 3375906. DOI: 10.1016/j.cell.2012.02.046. View

Spellman D, Wildsmith K, Honigberg L, Tuefferd M, Baker D, Raghavan N . Development and evaluation of a multiplexed mass spectrometry based assay for measuring candidate peptide biomarkers in Alzheimer's Disease Neuroimaging Initiative (ADNI) CSF. Proteomics Clin Appl. 2015; 9(7-8):715-31. PMC: 4739636. DOI: 10.1002/prca.201400178. View

Casaletto K, Elahi F, Bettcher B, Neuhaus J, Bendlin B, Asthana S . Neurogranin, a synaptic protein, is associated with memory independent of Alzheimer biomarkers. Neurology. 2017; 89(17):1782-1788. PMC: 5664306. DOI: 10.1212/WNL.0000000000004569. View

10.

van der Ende E, Meeter L, Stingl C, van Rooij J, Stoop M, Nijholt D . Novel CSF biomarkers in genetic frontotemporal dementia identified by proteomics. Ann Clin Transl Neurol. 2019; 6(4):698-707. PMC: 6469343. DOI: 10.1002/acn3.745. View

11.

Lange K, Bondi M, Salmon D, Galasko D, Delis D, Thomas R . Decline in verbal memory during preclinical Alzheimer's disease: examination of the effect of APOE genotype. J Int Neuropsychol Soc. 2002; 8(7):943-55. PMC: 1621042. DOI: 10.1017/s1355617702870096. View

12.

Wildsmith K, Schauer S, Smith A, Arnott D, Zhu Y, Haznedar J . Identification of longitudinally dynamic biomarkers in Alzheimer's disease cerebrospinal fluid by targeted proteomics. Mol Neurodegener. 2014; 9:22. PMC: 4061120. DOI: 10.1186/1750-1326-9-22. View

13.

Jack Jr C, Bennett D, Blennow K, Carrillo M, Dunn B, Budd Haeberlein S . NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. Alzheimers Dement. 2018; 14(4):535-562. PMC: 5958625. DOI: 10.1016/j.jalz.2018.02.018. View

14.

Hansson O, Seibyl J, Stomrud E, Zetterberg H, Trojanowski J, Bittner T . CSF biomarkers of Alzheimer's disease concord with amyloid-β PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts. Alzheimers Dement. 2018; 14(11):1470-1481. PMC: 6119541. DOI: 10.1016/j.jalz.2018.01.010. View

15.

Xiao M, Xu D, Craig M, Pelkey K, Chien C, Shi Y . NPTX2 and cognitive dysfunction in Alzheimer's Disease. Elife. 2017; 6. PMC: 5404919. DOI: 10.7554/eLife.23798. View

16.

Chang M, Park J, Pelkey K, Grabenstatter H, Xu D, Linden D . Narp regulates homeostatic scaling of excitatory synapses on parvalbumin-expressing interneurons. Nat Neurosci. 2010; 13(9):1090-7. PMC: 2949072. DOI: 10.1038/nn.2621. View

17.

Buckley R, Mormino E, Amariglio R, Properzi M, Rabin J, Lim Y . Sex, amyloid, and APOE ε4 and risk of cognitive decline in preclinical Alzheimer's disease: Findings from three well-characterized cohorts. Alzheimers Dement. 2018; 14(9):1193-1203. PMC: 6131023. DOI: 10.1016/j.jalz.2018.04.010. View

18.

Olsson B, Lautner R, Andreasson U, Ohrfelt A, Portelius E, Bjerke M . CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis. Lancet Neurol. 2016; 15(7):673-684. DOI: 10.1016/S1474-4422(16)00070-3. View

19.

Dowling N, Johnson S, Gleason C, Jagust W . The mediational effects of FDG hypometabolism on the association between cerebrospinal fluid biomarkers and neurocognitive function. Neuroimage. 2014; 105:357-68. PMC: 4262609. DOI: 10.1016/j.neuroimage.2014.10.050. View

20.

Sathe G, Na C, Renuse S, Madugundu A, Albert M, Moghekar A . Quantitative Proteomic Profiling of Cerebrospinal Fluid to Identify Candidate Biomarkers for Alzheimer's Disease. Proteomics Clin Appl. 2018; 13(4):e1800105. PMC: 6639119. DOI: 10.1002/prca.201800105. View